ACC 2019 preview – Medtronic seeks guidelines change with Tyrx data
A positive readout for Medtronic's Tyrx envelope could mean an extra $1,000 per cardiac implant in the company's pocket.
Deals galore for a new generation of transcatheter mitral valves
Transcatheter mitral valve replacement is wrenching the spotlight away from the repair devices that grabbed the headlines last summer.
Carmat’s heart sinks with another delay
Despite encouraging interim pivotal data, Carmat’s artificial heart seems as far from market as ever.
Boston and Edwards make a smart judgement
The immensely complex and long-running intertwined litigation between the two medtechs has been brought to an end.
Neurostimulation sham scuppers Mainstay
Mainstay Medical still hopes for US approval of its Reactiv8 device for chronic back pain despite trial failure.
Electrocore goes for the throat with non-invasive neuromodulator
The world’s first non-implanted vagus nerve stimulator is becoming established as a therapy for headache and migraine. But a move into autoimmune conditions will require…
Roche leaves Abbott in the dust when it comes to US approval times
The Swiss group has succeeded with its internally developed diagnostics, but buying in innovation has served Becton Dickinson well.
Portico has its foot in the door, but various trials await
Abbott Laboratories has posted decent results for its transcatheter aortic valve, but all-important US pivotal data are in the offing.
Medtronic spends $1.6bn to finish what it started with Mazor
The industry leader’s biggest buy since Covidien gets it into robots, but direct competition with Intuitive is unlikely.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.